The Experts below are selected from a list of 2139 Experts worldwide ranked by ideXlab platform

John B Buse - One of the best experts on this subject based on the ideXlab platform.

  • one year efficacy and safety of a fixed combination of Insulin Degludec and liraglutide in patients with type 2 diabetes results of a 26 week extension to a 26 week main trial
    Diabetes Obesity and Metabolism, 2015
    Co-Authors: Stephen C. L. Gough, Vincent Woo, B Bode, Helena W Rodbard, Sultan Linjawi, M Zacho, P D Reiter, John B Buse
    Abstract:

    Aims To confirm, in a 26-week extension study, the sustained efficacy and safety of a fixed combination of Insulin Degludec and liraglutide (IDegLira) compared with either Insulin Degludec or liraglutide alone, in patients with type 2 diabetes. Methods Insulin-naive adults with type 2 diabetes randomized to once-daily IDegLira, Insulin Degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial. Results A total of 78.8% of patients (1311/1663) continued into the extension phase. The mean glycated haemoglobin (HbA1c) concentration at 52 weeks was reduced from baseline by 1.84% (20.2 mmol/mol) for the IDegLira group, 1.40% (15.3 mmol/mol) for the Insulin Degludec group and 1.21% (13.2 mmol/mol) for the liraglutide group. Of the patients on IDegLira, 78% achieved an HbA1c of <7% (53 mmol/mol) versus 63% of the patients on Insulin Degludec and 57% of those on liraglutide. The mean fasting plasma glucose concentration at the end of the trial was similar for IDegLira (5.7 mmol/l) and Insulin Degludec (6.0 mmol/l), but higher for liraglutide (7.3 mmol/l). At 52 weeks, the daily Insulin dose was 37% lower with IDegLira (39 units) than with Insulin Degludec (62 units). IDegLira was associated with a significantly greater decrease in body weight (estimated treatment difference, −2.80 kg, p < 0.0001) and a 37% lower rate of hypoglycaemia compared with Insulin Degludec. Overall, all treatments were well tolerated and no new adverse events or tolerability issues were observed for IDegLira. Conclusions These 12-month data, derived from a 26-week extension of the DUAL I trial, confirm the initial 26-week main phase results and the sustainability of the benefits of IDegLira compared with its components in glycaemic efficacy, safety and tolerability.

  • One‐year efficacy and safety of a fixed combination of Insulin Degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial
    Diabetes obesity & metabolism, 2015
    Co-Authors: Stephen C. L. Gough, Vincent Woo, B Bode, Helena W Rodbard, M Zacho, P D Reiter, Linjawi, John B Buse
    Abstract:

    Aims To confirm, in a 26-week extension study, the sustained efficacy and safety of a fixed combination of Insulin Degludec and liraglutide (IDegLira) compared with either Insulin Degludec or liraglutide alone, in patients with type 2 diabetes. Methods Insulin-naive adults with type 2 diabetes randomized to once-daily IDegLira, Insulin Degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial. Results A total of 78.8% of patients (1311/1663) continued into the extension phase. The mean glycated haemoglobin (HbA1c) concentration at 52 weeks was reduced from baseline by 1.84% (20.2 mmol/mol) for the IDegLira group, 1.40% (15.3 mmol/mol) for the Insulin Degludec group and 1.21% (13.2 mmol/mol) for the liraglutide group. Of the patients on IDegLira, 78% achieved an HbA1c of

  • efficacy and safety of a fixed ratio combination of Insulin Degludec and liraglutide ideglira compared with its components given alone results of a phase 3 open label randomised 26 week treat to target trial in Insulin naive patients with type 2 diab
    The Lancet Diabetes & Endocrinology, 2014
    Co-Authors: Stephen C. L. Gough, Vincent Woo, Helena W Rodbard, Sultan Linjawi, Bruce W Bode, Pernille Poulsen, L H Damgaard, John B Buse
    Abstract:

    Summary Background A fixed-ratio combination of the basal Insulin analogue Insulin Degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide has been developed as a once-daily injection for the treatment of type 2 diabetes. We aimed to compare combined Insulin Degludec–liraglutide (IDegLira) with its components given alone in Insulin-naive patients. Methods In this phase 3, 26-week, open-label, randomised trial, adults with type 2 diabetes, HbA 1c of 7–10% (inclusive), a BMI of 40 kg/m 2 or less, and treated with metformin with or without pioglitazone were randomly assigned (2:1:1) to daily injections of IDegLira, Insulin Degludec, or liraglutide (1·8 mg per day). IDegLira and Insulin Degludec were titrated to achieve a self-measured prebreakfast plasma glucose concentration of 4–5 mmol/L. The primary endpoint was change in HbA 1c after 26 weeks of treatment, and the main objective was to assess the non-inferiority of IDegLira to Insulin Degludec (with an upper 95% CI margin of 0·3%), and the superiority of IDegLira to liraglutide (with a lower 95% CI margin of 0%). This study is registered with ClinicalTrials.gov, number NCT01336023. Findings 1663 adults (mean age 55 years [SD 10], HbA 1c 8·3% [0·9], and BMI 31·2 kg/m 2 [4·8]) were randomly assigned, 834 to IDegLira, 414 to Insulin Degludec, and 415 to liraglutide. After 26 weeks, mean HbA 1c had decreased by 1·9% (SD 1·1) to 6·4% (1·0) with IDegLira, by 1·4% (1·0) to 6·9% (1·1) with Insulin Degludec, and by 1·3% (1·1) to 7·0% (1·2) with liraglutide. IDegLira was non-inferior to Insulin Degludec (estimated treatment difference −0·47%, 95% CI −0·58 to −0·36, p vs 19·7%), although the Insulin Degludec group had the fewest participants with gastrointestinal adverse events (nausea 3·6%). We noted no clinically relevant differences between treatments with respect to standard safety assessments, and the safety profile of IDegLira reflected those of its component parts. The number of confirmed hypoglycaemic events per patient year was 1·8 for IDegLira, 0·2 for liraglutide, and 2·6 for Insulin Degludec. Serious adverse events occurred in 19 (2%) of 825 patients in the IDegLira group, eight (2%) of 412 in the Insulin Degludec group, and 14 (3%) of 412 in the liraglutide group. Interpretation IDegLira combines the clinical advantages of basal Insulin and GLP-1 receptor agonist treatment, resulting in improved glycaemic control compared with its components given alone. Funding Novo Nordisk.

  • Insulin Degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than Insulin glargine in basal bolus treatment with mealtime Insulin aspart in type 1 diabetes begin basal bolus type 1 2 year results of a randomized clinical trial
    Diabetic Medicine, 2013
    Co-Authors: Bruce W Bode, Michel Marre, Éric Renard, John B Buse, Charlotte T Hansen, Miles Fisher, Satish K Garg, L Merker, D L Russelljones, A Rana
    Abstract:

    Aims The goal of this study was to compare the long-term safety and efficacy of the basal Insulin analogue, Insulin Degludec with Insulin glargine (both with Insulin aspart) in Type 1 diabetes, over a 2-year time period. Methods This open-label trial comprised a 1-year main trial and a 1-year extension. Patients were randomized to once-daily Insulin Degludec or Insulin glargine and titrated to pre-breakfast plasma glucose values of 3.9–4.9 mmol/l. Results The rate of nocturnal confirmed hypoglycaemia was 25% lower with Insulin Degludec than with Insulin glargine (P = 0.02). Rates of confirmed hypoglycaemia, severe hypoglycaemia and adverse events, and reductions in glycated haemoglobin and fasting plasma glucose were similar between groups. Despite achieving similar glycaemic control, Insulin Degludec-treated patients used 12% less basal and 9% less total daily Insulin than did Insulin glargine-treated patients (P < 0.01). Conclusions Long-term basal therapy using Insulin Degludec in Type 1 diabetes required lower doses and was associated with a 25% lower risk for nocturnal hypoglycaemia than Insulin glargine.

Vincent Woo - One of the best experts on this subject based on the ideXlab platform.

  • A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus.
    Clinical Therapeutics, 2017
    Co-Authors: Vincent Woo
    Abstract:

    Abstract Purpose The treatment of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) using Insulin is not ideal at this time. Despite advances made with basal Insulin analogues, many individuals achieve less than optimal glycemic control or are at risk for hypoglycemia. Currently available basal Insulin analogues do not deliver steady, peakless, continuous Insulin for >24 hours and are associated with adverse events, including hypoglycemia. The objective of this paper was to review the clinical efficacy and safety of upcoming long-acting Insulin analogues such as Insulin Degludec and Insulin glargine 300 U/mL (Gla-300). Methods A comprehensive literature search of PubMed and Google Scholar was conducted from 1966 to 2015. The search included randomized controlled trials that specifically assessed the efficacy and safety of Insulin Degludec and Gla-300 in patients with T1DM and T2DM. Findings The efficacy of Insulin Degludec and Gla-300 in achieving glycemic control has been reported in clinical trials in adults with T1DM and T2DM. Not only did a large number of patients succeed in meeting glycosylated hemoglobin targets, but they also experienced reductions in hypoglycemic events. These 2 therapies are associated with a reduced risk of nocturnal hypoglycemia and are generally well tolerated. Implications The long-acting Insulin analogues Insulin Degludec and Gla-300 are promising therapies in the treatment of T1DM and T2DM. Their improved Insulin delivery for >24 hours offers glycemic control with a good safety profile.

  • Insulin Degludec liraglutide ideglira for the treatment of type 2 diabetes
    Expert Review of Endocrinology & Metabolism, 2016
    Co-Authors: Stephen C. L. Gough, Rajeev Jain, Vincent Woo
    Abstract:

    The progressive nature of type 2 diabetes necessitates that treatment is intensified as the disease advances. Several studies have shown that basal Insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) can be used in combination to successfully improve glycemic control and this combination is increasingly being considered as an alternative to intensification with prandial Insulin. Insulin Degludec/liraglutide (IDegLira) is the first fixed-ratio combination of a basal Insulin and a GLP-1RA in a single formulation. Here we consider the benefits and potential limitations of such a combination, focusing on the unique modes of action of Insulin Degludec and the once-daily GLP-1RA liraglutide. IDegLira offers an efficacious combination therapy (mean end-of-trial HbA1c was 6.4-6.9% across the five completed Phase 3 trials), which was well-tolerated in clinical trials. The complementary modes of action resulted in a low rate of hypoglycemia and no weight gain in Insulin-treated patients. As a once-daily injection with effects on both fasting and post prandial hyperglycemia, IDegLira has the potential to help many patients reach glycemic target (60-81% of patients achieved HbA1c <7% in clinical trials).

  • Insulin Degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes.
    Expert review of endocrinology & metabolism, 2015
    Co-Authors: Stephen C. L. Gough, Rajeev Jain, Vincent Woo
    Abstract:

    The progressive nature of type 2 diabetes necessitates that treatment is intensified as the disease advances. Several studies have shown that basal Insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) can be used in combination to successfully improve glycemic control and this combination is increasingly being considered as an alternative to intensification with prandial Insulin. Insulin Degludec/liraglutide (IDegLira) is the first fixed-ratio combination of a basal Insulin and a GLP-1RA in a single formulation. Here we consider the benefits and potential limitations of such a combination, focusing on the unique modes of action of Insulin Degludec and the once-daily GLP-1RA liraglutide. IDegLira offers an efficacious combination therapy (mean end-of-trial HbA1c was 6.4-6.9% across the five completed Phase 3 trials), which was well-tolerated in clinical trials. The complementary modes of action resulted in a low rate of hypoglycemia and no weight gain in Insulin-treated patients. As a once-daily injection with effects on both fasting and post prandial hyperglycemia, IDegLira has the potential to help many patients reach glycemic target (60-81% of patients achieved HbA1c

  • one year efficacy and safety of a fixed combination of Insulin Degludec and liraglutide in patients with type 2 diabetes results of a 26 week extension to a 26 week main trial
    Diabetes Obesity and Metabolism, 2015
    Co-Authors: Stephen C. L. Gough, Vincent Woo, B Bode, Helena W Rodbard, Sultan Linjawi, M Zacho, P D Reiter, John B Buse
    Abstract:

    Aims To confirm, in a 26-week extension study, the sustained efficacy and safety of a fixed combination of Insulin Degludec and liraglutide (IDegLira) compared with either Insulin Degludec or liraglutide alone, in patients with type 2 diabetes. Methods Insulin-naive adults with type 2 diabetes randomized to once-daily IDegLira, Insulin Degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial. Results A total of 78.8% of patients (1311/1663) continued into the extension phase. The mean glycated haemoglobin (HbA1c) concentration at 52 weeks was reduced from baseline by 1.84% (20.2 mmol/mol) for the IDegLira group, 1.40% (15.3 mmol/mol) for the Insulin Degludec group and 1.21% (13.2 mmol/mol) for the liraglutide group. Of the patients on IDegLira, 78% achieved an HbA1c of <7% (53 mmol/mol) versus 63% of the patients on Insulin Degludec and 57% of those on liraglutide. The mean fasting plasma glucose concentration at the end of the trial was similar for IDegLira (5.7 mmol/l) and Insulin Degludec (6.0 mmol/l), but higher for liraglutide (7.3 mmol/l). At 52 weeks, the daily Insulin dose was 37% lower with IDegLira (39 units) than with Insulin Degludec (62 units). IDegLira was associated with a significantly greater decrease in body weight (estimated treatment difference, −2.80 kg, p < 0.0001) and a 37% lower rate of hypoglycaemia compared with Insulin Degludec. Overall, all treatments were well tolerated and no new adverse events or tolerability issues were observed for IDegLira. Conclusions These 12-month data, derived from a 26-week extension of the DUAL I trial, confirm the initial 26-week main phase results and the sustainability of the benefits of IDegLira compared with its components in glycaemic efficacy, safety and tolerability.

  • One‐year efficacy and safety of a fixed combination of Insulin Degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial
    Diabetes obesity & metabolism, 2015
    Co-Authors: Stephen C. L. Gough, Vincent Woo, B Bode, Helena W Rodbard, M Zacho, P D Reiter, Linjawi, John B Buse
    Abstract:

    Aims To confirm, in a 26-week extension study, the sustained efficacy and safety of a fixed combination of Insulin Degludec and liraglutide (IDegLira) compared with either Insulin Degludec or liraglutide alone, in patients with type 2 diabetes. Methods Insulin-naive adults with type 2 diabetes randomized to once-daily IDegLira, Insulin Degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial. Results A total of 78.8% of patients (1311/1663) continued into the extension phase. The mean glycated haemoglobin (HbA1c) concentration at 52 weeks was reduced from baseline by 1.84% (20.2 mmol/mol) for the IDegLira group, 1.40% (15.3 mmol/mol) for the Insulin Degludec group and 1.21% (13.2 mmol/mol) for the liraglutide group. Of the patients on IDegLira, 78% achieved an HbA1c of

Genshi Egusa - One of the best experts on this subject based on the ideXlab platform.

Stephen L Atkin - One of the best experts on this subject based on the ideXlab platform.

  • multinational consensus Insulin initiation with Insulin Degludec aspart idegasp
    Advances in Therapy, 2018
    Co-Authors: Sanjay Kalra, Antonio Cervera, Md. Fariduddin, Özgür Demir, Tevfik Demir, Stephen L Atkin, Ashok Kumar Das, Ajay Kumar, Zafar Ahmed Latif, Rachid Malek
    Abstract:

    Insulin Degludec/aspart (IDegAsp) is the first soluble Insulin co-formulation, combining a long-acting Insulin Degludec (IDeg) and rapid-acting Insulin aspart (IAsp). In type 2 diabetes patients with oral antidiabetes agent (OAD) inadequacy, Insulin initiation with IDegAsp once daily provides superior long-term glycemic control compared to Insulin glargine, with similar fasting plasma glucose (FPG) and Insulin doses, and numerically lower rates of overall and nocturnal hypoglycemia. Furthermore, in patients with uncontrolled type 2 diabetes previously treated with Insulins, IDegAsp twice daily effectively improves glycated hemoglobin and FPG, with fewer hypoglycemic episodes versus premix Insulins and basal bolus therapy. In patients with type 1 diabetes mellitus, IDegAsp once daily with two doses of IAsp is a convenient, yet effective, regimen as compared to the conventional 4–5 injection-based basal bolus therapy. IDegAsp is an appropriate and reasonable option for initiation of Insulin therapy in both type 1 and type 2 diabetes.

  • Insulin Degludec and Insulin aspart: novel Insulins for the management of diabetes mellitus.
    Therapeutic Advances in Chronic Disease, 2015
    Co-Authors: Stephen L Atkin, Zeeshan Javed, Gregory R. Fulcher
    Abstract:

    Patients with type 2 diabetes mellitus require Insulin as disease progresses to attain or maintain glycaemic targets. Basal Insulin is commonly prescribed initially, alone or with one or more rapid-acting prandial Insulin doses, to limit mealtime glucose excursions (a basal–bolus regimen). Both patients and physicians must balance the advantages of improved glycaemic control with the risk of hypoglycaemia and increasing regimen complexity. The rapid-acting Insulin analogues (Insulin aspart, Insulin lispro and Insulin glulisine) all have similar pharmacokinetic and pharmacodynamic characteristics and clinical efficacy/safety profiles. However, there are important differences in the pharmacokinetic and pharmacodynamic profiles of basal Insulins (Insulin glargine, Insulin detemir and Insulin Degludec). Insulin Degludec is an ultra-long-acting Insulin analogue with a flat and stable glucose-lowering profile, a duration of action exceeding 30 h and less inter-patient variation in glucose-lowering effect than Insulin glargine. In particular, the chemical properties of Insulin Degludec have allowed the development of a soluble co-formulation with prandial Insulin aspart (Insulin Degludec/Insulin aspart) that provides basal Insulin coverage for at least 24 h with additional mealtime Insulin for one or two meals depending on dose frequency. Pharmacokinetic and pharmacodynamic studies have shown that the distinct, long basal glucose-lowering action of Insulin Degludec and the prandial glucose-lowering effect of Insulin aspart are maintained in the co-formulation. Evidence from pivotal phase III clinical trials indicates that Insulin Degludec/Insulin aspart translate into sustained glycaemic control with less hypoglycaemia and the potential for a simpler Insulin regimen with fewer daily injections.

  • Insulin Degludec--a new-generation basal Insulin.
    Expert opinion on biological therapy, 2012
    Co-Authors: Ammar Wakil, Stephen L Atkin
    Abstract:

    Insulin Degludec may provide dosing options for patients who, because of their lifestyle, require some flexibility in adhering to an Insulin regimen, and it may also reduce the risk of hypoglycemia compared with the basal Insulins that are currently available.

  • Efficacy and safety of ultra-long-acting Insulin Degludec
    Therapeutic advances in endocrinology and metabolism, 2012
    Co-Authors: Ammar Wakil, Stephen L Atkin
    Abstract:

    All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with Insulin. Nonadherence to Insulin regimen can impact glycaemic control. Insulin Degludec is a new generation, ultra-long-acting basal Insulin that forms soluble multihexamers at the injection site that slowly release Insulin Degludec monomers into the circulation giving a prolonged duration of action. Insulin Degludec may provide a safe and convenient dosing option for patients who require some flexibility in adhering to an Insulin regimen according to their lifestyle or circumstances. In this review we focus on the early phases of Insulin Degludec development.

Sanjay Kalra - One of the best experts on this subject based on the ideXlab platform.

  • Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)
    Advances in Therapy, 2018
    Co-Authors: Sanjay Kalra, Stephen Atkin, Antonio Cervera, Md. Fariduddin, Khoa Tuan Vo, Özgür Demir, Tevfik Demir, Bon Jeong Ku, Ashok Kumar Das, Ajay Kumar
    Abstract:

    Insulin Degludec/aspart (IDegAsp) is the first soluble Insulin co-formulation, combining a long-acting Insulin Degludec (IDeg) and rapid-acting Insulin aspart (IAsp). In type 2 diabetes patients with oral antidiabetes agent (OAD) inadequacy, Insulin initiation with IDegAsp once daily provides superior long-term glycemic control compared to Insulin glargine, with similar fasting plasma glucose (FPG) and Insulin doses, and numerically lower rates of overall and nocturnal hypoglycemia. Furthermore, in patients with uncontrolled type 2 diabetes previously treated with Insulins, IDegAsp twice daily effectively improves glycated hemoglobin and FPG, with fewer hypoglycemic episodes versus premix Insulins and basal bolus therapy. In patients with type 1 diabetes mellitus, IDegAsp once daily with two doses of IAsp is a convenient, yet effective, regimen as compared to the conventional 4–5 injection-based basal bolus therapy. IDegAsp is an appropriate and reasonable option for initiation of Insulin therapy in both type 1 and type 2 diabetes.

  • multinational consensus Insulin initiation with Insulin Degludec aspart idegasp
    Advances in Therapy, 2018
    Co-Authors: Sanjay Kalra, Antonio Cervera, Md. Fariduddin, Özgür Demir, Tevfik Demir, Stephen L Atkin, Ashok Kumar Das, Ajay Kumar, Zafar Ahmed Latif, Rachid Malek
    Abstract:

    Insulin Degludec/aspart (IDegAsp) is the first soluble Insulin co-formulation, combining a long-acting Insulin Degludec (IDeg) and rapid-acting Insulin aspart (IAsp). In type 2 diabetes patients with oral antidiabetes agent (OAD) inadequacy, Insulin initiation with IDegAsp once daily provides superior long-term glycemic control compared to Insulin glargine, with similar fasting plasma glucose (FPG) and Insulin doses, and numerically lower rates of overall and nocturnal hypoglycemia. Furthermore, in patients with uncontrolled type 2 diabetes previously treated with Insulins, IDegAsp twice daily effectively improves glycated hemoglobin and FPG, with fewer hypoglycemic episodes versus premix Insulins and basal bolus therapy. In patients with type 1 diabetes mellitus, IDegAsp once daily with two doses of IAsp is a convenient, yet effective, regimen as compared to the conventional 4–5 injection-based basal bolus therapy. IDegAsp is an appropriate and reasonable option for initiation of Insulin therapy in both type 1 and type 2 diabetes.

  • Insulin Degludec and Insulin Degludec/Insulin aspart in Ramadan: A single center experience.
    Indian journal of endocrinology and metabolism, 2016
    Co-Authors: Sanjay Kalra
    Abstract:

    This study aimed to document the utility and safety of Insulin Degludec (IDeg) and Insulin Degludec aspart (IDegAsp) in persons with type 2 diabetes, observing the Ramadan fast. An observational study was conducted at a single center, in the real world setting, on six persons who either switched to IDeg or IDegAsp a month before Ramadan or changed time of administration of IDegAsp at the onset of Ramadan, to keep the fast in a safe manner. Subjects were kept under regular monitoring and surveillance before, during, and after Ramadan, and counseled in an opposite manner. Four persons, who shifted from premixed Insulin to IDegAsp, experienced a 12-18% dose reduction after 14 days. At the onset of Ramadan, the Suhur dose was reduced by 30%, and this remained unchanged during the fasting month. The Iftar dose had to be increased by 4 units. One person who shifted from neutral protamine hagedorn to IDeg demonstrated a 25% dose reduction at 20 days, without any further change in Insulin requirement during Ramadan. One person who changed time of injection of IDegAsp from morning to night reported no change in dosage. No episode of major hypoglycemia was reported. IDeg and IDegAsp are effective, safe, and well-tolerated means of achieving glycemic control in persons with type 2 diabetes who wish to fast.

  • Pragmatic use of Insulin Degludec/Insulin aspart co-formulation: A multinational consensus statement.
    Indian journal of endocrinology and metabolism, 2016
    Co-Authors: Sanjay Kalra, Zafar Ahmed Latif, Abdurrahman Comlekci, Guillermo González Gálvez, Rached Malik, Faruque Pathan, Ajay Kumar
    Abstract:

    Insulin Degludec/Insulin aspart (IDegAsp) is a modern coformulation of ultra-long-acting basal Insulin Degludec, with rapid-acting Insulin aspart. IDegAsp provides effective, safe, well-tolerated glycemic control, with a low risk of hypoglycemia while allowing flexibility in meal patterns and timing of administration. This consensus statement describes a pragmatic framework to identify patients who may benefit from IDegAsp therapy. It highlights the utility of IDegAsp in type 2 diabetic patients who are Insulin-naive, suboptimally controlled on basal or premixed Insulin, or dissatisfied with basal-bolus regimens. It also describes potential IDegAsp usage in type 1 diabetic patients.

  • Clinical use of Insulin Degludec: Practical experience and pragmatic suggestions
    North American journal of medical sciences, 2015
    Co-Authors: Sanjay Kalra, Yashdeep Gupta
    Abstract:

    Insulin Degludec (IDeg) is an ultralong acting basal Insulin. IDeg has unique pharmacokinetic and pharmacodynamic properties which allow once a daily dosage, at any time of the day. Its use is associated with a significantly lower risk of hypoglycemia. This review discusses the pragmatic use of IDeg, based on available evidence. A complete search of all nine original research papers (BEGIN® clinical trial program) pertaining to IDeg, listed in PubMed, was made to prepare this article.